Skip to content
Simpler Grants

No. PAR-25-297 · National Institutes of Health

Open

Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)

grants.gov listing Full announcement (NOFO)
Dealbreakers No cost share required Audit: not stated
Not reimbursement-only
“Cooperative Agreement: A financial assistance mechanism used when there will be substantial Federal scientific or programmatic involvement.” — From the announcement
Award range
Up to $1,500,000
Expected awards
Not specified
Application deadline
Nov 5, 2027
Posted
Dec 4, 2024
Last verified
8 days ago

At a glance

AI summary

This program funds drug development for Alzheimer’s disease, including work on small molecules, natural products, and biologics, from early optimization through IND-enabling studies and initial Phase I clinical testing. Eligible applicants are researchers with projects that fit the program’s early or late stage entry criteria; the notice does not state award size or number of awards in the text provided. No cost-share requirement is stated. The program is limited to drug development for Alzheimer’s disease and excludes basic research, stand-alone efficacy studies, stand-alone clinical trials, studies beyond Phase I, anti-amyloid and anti-tau immunotherapies, generic or off-patent compounds, repurposing or new formulations of previously approved compounds, combination therapies, and biomarker or diagnostic projects.

AI-generated summary — verify against the announcement

What it funds

  • Health
  • Technology & Product Development
  • Patients & People with Health Conditions
  • Biomedical & Disease Research
Official description from grants.gov

The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET); efficacy in animal models; development of biomarkers for target engagement; formulation development; chemical synthesis under Good Manufacturing Practices (GMP); Investigational New Drug (IND) enabling studies; and initial Phase I clinical testing. Applications not responsive to this NOFO include research on basic mechanisms of disease or mechanisms of drug action; development ofrisk, diagnostic, prognostic, predictive, and preventionbiomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combination therapies; discovery activities such as high-throughput screening and hit optimization; and stand-alone clinical trials.

Who can apply

  • City or township governments
  • County governments
  • For-profit organizations other than small businesses
  • Independent school districts
  • Native American tribal governments (Federally recognized)
  • Native American tribal organizations (other than Federally recognized)
  • Nonprofits with 501(c)(3) status (other than higher education)
  • Nonprofits without 501(c)(3) status (other than higher education)
  • Others
  • Private institutions of higher education
  • Public and State controlled institutions of higher education
  • Public housing authorities / Indian housing authorities
  • Small businesses
  • Special district governments
  • State governments
Geographic restriction None found in the announcement — likely nationwide

Program history

USASpending.gov

Assistance listing 93.866 · Aging Research

Real awards this federal program has made — the whole assistance listing (93.866), not just this notice.

Fiscal year Awards Median award Middle half
FY 2026 (so far) 795 $493,972 $248,999 – $713,195
FY 2025 1,033 $643,089 $467,538 – $1,733,010
FY 2024 1,560 — —
FY 2023 1,539 — —
FY 2022 1,715 — —
FY 2021 1,595 — —

For comparison, this notice advertises Up to $1,500,000.

Dollar figures are based on the 1,000 most recent awards we store, not all 8,237 — award counts are complete.

Who wins it Higher education (6,015), Nonprofit (1,370), Business (538) of 8,237 awards — categories can overlap.
Top states CA (153) · NY (110) · MA (100) · TX (57) · PA (41)
Largest recent awards
  1. REGENTS OF THE UNIVERSITY OF MICHIGAN $15,345,206 · FY 2026
  2. UNIVERSITY OF UTAH $10,793,501 · FY 2025
  3. THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK $10,223,348 · FY 2026
  4. SUTTER BAY HOSPITALS $9,466,491 · FY 2025
  5. TUFTS MEDICAL CENTER PARENT, INC. $8,296,115 · FY 2026

Source: USASpending.gov · refreshed Aug 23, 2026